Michael E. Williams
Abstract
Cladribine monotherapy yields a high response rate and durable remission for most patients with hairy cell leukemia (HCL), usually with only one
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Cladribine monotherapy yields a high response rate and durable remission for most patients with hairy cell leukemia (HCL), usually with only one
Key concepts: Cladribine, Medicine, Hairy cell leukemia, Schedule, Oncology, Leukemia, Intensive care medicine, Internal medicine